EUVIMEDEUVIMED entdecken
Crossref

ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer

Shen-Nan Shi, Qiuyang Xu, Zhiqi Liao, Wenjian Gong, Yilin Cui, Jiahao Liu, Xiaofei Jiao, Yijie Wu, Mengshi Luo, Yuewen Zhang, Linghui Wang, Yuanjia Wen und 9 weitere

Drug Resistance Updates · 2026-01 · 84 · 101319

DOI: 10.1016/j.drup.2025.101319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-01. Verfasst von Shen-Nan Shi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Hu…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Ovarian Neoplasms, MRE11 Homologue Protein. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China, Foundation for Innovative Research Groups of Hubei Province of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ZBP1, a classic pattern recognition receptor (PRR), has been implicated in regulating programmed cell death and the innate immune response. However, the role of ZBP1 in the nucleus remains largely undefined. Here, we found that nuclear ZBP1 localizes to the site of DNA double-stranded breaks (DSBs) following DNA damage and impairs homologous recombination (HR) repair through its interaction with MRE11. ZBP1 interacts with MRE11 through RHIM A and B domains and inhibits the enzymatic activity of MRE11, ultimately leading to the suppression of HR and DNA damage repair (DDR). These processes are initiated via ATM-mediated ZBP1 phosphorylation at S106. Consistent with these findings, in vitro and in vivo models both exhibit increased sensitivity to PARP inhibitor treatment following ZBP1 overexpression. Furthermore, in our neoadjuvant niraparib monotherapy study (NCT05407841) higher ZBP1 expression correlates with better response to PARP inhibition and prolonged PFS in high-grade serous ovarian cancer (HGSOC). This study describes a novel function of ZBP1 for regulating HR, which confers synthetic lethality to PARP inhibition in ovarian cancer. ZBP1 thus serves as a potential therapy target and biomarker of response to PARP inhibitors and potentially other therapeutic agents such as platin analogs that are synthetically lethal with defective HR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsOvarian NeoplasmsMRE11 Homologue ProteinFemaleHumansAnimalsMiceCell Line, TumorSynthetic Lethal MutationsDNA Breaks, Double-StrandedPiperidinesRecombinational DNA RepairXenograft Model Antitumor AssaysIndazoles

Stichwörter der Autor:innen

DNA damage responseHomologous recombinationOvarian cancerPARP inhibitorZBP1

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsMRE11 Homologue ProteinMRE11 protein, humanniraparibPiperidinesIndazoles

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Key Laborat…
  • Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
  • Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.
  • Mills institute for Personalized Cancer Care, Fynn Biotechnologies Ltd., Jinan 250101, China.
  • Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States.

Förderung

  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China
  • Foundation for Innovative Research Groups of Hubei Province of China
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Breast Cancer Research Foundation
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Zitieren

APA

Shi, S. N., Xu, Q., Liao, Z., Gong, W., Cui, Y., Liu, J., Jiao, X., Wu, Y., Luo, M., Zhang, Y., Wang, L., Wen, Y., Pan, W., Zhao, X., Labrie, M., Ding, Z., Mills, G. B., Ma, D., Zhao, G. N., …, & Fang, Y. (2026). ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer. Drug Resistance Updates, 84, 101319. https://doi.org/10.1016/j.drup.2025.101319

Vancouver

Shi SN, Xu Q, Liao Z, Gong W, Cui Y, Liu J, et al. ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer. Drug Resistance Updates. 2026;84:101319. doi:10.1016/j.drup.2025.101319

BibTeX
@article{Shi2026,
  author = {Shi, Shen-Nan and Xu, Qiuyang and Liao, Zhiqi and Gong, Wenjian and Cui, Yilin and Liu, Jiahao and Jiao, Xiaofei and Wu, Yijie and Luo, Mengshi and Zhang, Yuewen and Wang, Linghui and Wen, Yuanjia and Pan, Wen and Zhao, Xuejiao and Labrie, Marilyne and Ding, Zhiyong and Mills, Gordon B and Ma, Ding and Zhao, Guang-Nian and Gao, Qinglei and Fang, Yong},
  title = {ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {84},
  pages = {101319},
  doi = {10.1016/j.drup.2025.101319}
}
Kostenlos starten →